2015 Clinical trials update in sickle cell anemia

American Journal of Hematology

Volumn 90, Issue 10, 2015, Pages 934-950

  Archer, Natasha ^a   Galacteros, Frédéric ^b   Brugnara, Carlo ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HENRI MONDOR HOSPITAL   (France)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISICKLING AGENT; HEMOGLOBIN F; HEMOGLOBIN S; OXYGEN;

ARTICLE; CELL ADHESION; CELL THERAPY; CLINICAL TRIAL (TOPIC); ENDOTHELIUM; ERYTHROCYTE; GENE THERAPY; HUMAN; IRON OVERLOAD; OXIDATIVE STRESS; OXYGEN AFFINITY; PAIN; PATHOPHYSIOLOGY; POLYMERIZATION; PRIORITY JOURNAL; SICKLE CELL; SICKLE CELL ANEMIA; VASCULAR DISEASE; ANEMIA, SICKLE CELL; BLOOD; COMPLICATION; ERYTHROCYTE DISORDER; METABOLISM; VASCULAR DISEASES;

ANEMIA, SICKLE CELL; CLINICAL TRIALS AS TOPIC; ERYTHROCYTES, ABNORMAL; HEMOGLOBIN, SICKLE; HUMANS; OXYGEN; VASCULAR DISEASES;

EID: 84942104961     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24116     Document Type: Article

References (170)

1. Ballas SK, Lieff, S, Benjamin LJ, et al. Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol 2010; 85:6-13.
2. Yawn BP, Buchanan, GR, Afenyi-Annan AN, et al. Management of sickle cell disease: Summary of the 2014 evidence-based report by expert panel members. JAMA 2014; 312:1033-1048.
3. Habibi A, Arlet, JB, Stankovic K, et al. [French guidelines for the management of adult sickle cell disease: 2015 update]. Rev Med Intern 2015; 36:5S3-5S84.
4. Beverung LM, Strouse, JJ, Hulbert ML, et al. Health-related quality of life in children with sickle cell anemia: Impact of blood transfusion therapy. Am J Hematol 2015; 90:139-143.
5. http://www.nih.gov/news/health/nov2014/nhlbi-0000.htm. Last accessed on July 28, 2015.
6. Angelucci E, Matthes-Martin, S, Baronciani D, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: Indications and management recommendations from an international expert panel. Haematologica 2014; 99:811-820.
7. Hsieh MM, Fitzhugh CD, Tisdale JF. Allogeneic hematopoietic stem cell transplantation for sickle cell disease: The time is now. Blood 2011; 118:1197-1207.
8. Sunshine HR, Hofrichter J, Eaton WA. Requirements for therapeutic inhibition of sickle hemoglobin gelation. Nature 1978; 275:238-240.
9. Eaton WA, Hofrichter J. Hemoglobin S gelation and sickle cell disease. Blood 1987; 70:1245-1266.
10. Eaton WA, Hofrichter J. Sickle cell hemoglobin polymerization. Adv Prot Chem 1990; 40:63-279.
11. Eaton WA, Hofrichter J. The biophysics of sickle cell hydroxyurea therapy. Science 1995; 268:1142-1143.
12. Quarmyne M-O Rayes, O, Gonsalves CS, et al. A phase I trial of zileuton in sickle cell disease. Blood 2013; 122:993-993.
13. Field JJ Lin, G, Okam MM, et al. Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. Blood 2013; 121:3329-3334.
14. Minniti CP, Gorbach, AM, Xu D, et al. Topical sodium nitrite for chronic leg ulcers in patients with sickle cell anaemia: A phase 1 dose-finding safety and tolerability trial. Lancet Haematol 2014; 1:e95-e103.
15. Reid ME, El Beshlawy, A, Inati A, et al. A double-blind, placebo-controlled phase II study of the efficacy and safety of 2, 2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol 2014; 89:709-713.
16. Desai PC, Brittain, JE, Jones SK, et al. A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease. Thromb Res 2013; 132:341-345.
17. Goldman RD, Mounstephen, W, Kirby-Allen M, et al. Intravenous magnesium sulfate for vaso-occlusive episodes in sickle cell disease. Pediatrics 2013; 132:E1634-E1641.
18. Ferrone FA. The delay time in sickle cell disease after 40 years: A paradigm assessed. Am J Hematol 2015; 438-445.
19. Platt OS, Thorington, BD, Brambilla DJ, et al. Pain in sickle-cell disease - Rates and risk-factors. N Engl J Med 1991; 325:11-16.
20. Platt OS, Brambilla, DJ, Rosse WF, et al. Mortality in sickle-cell disease - Life expectancy and risk-factors for early death. N Engl J Med 1994; 330:1639-1644.
21. Alsultan A, Ngo, D, Bae H, et al. Genetic studies of fetal hemoglobin in the Arab-Indian haplotype sickle cell-β0 thalassemia. Am J Hematol 2013; 88:531-532.
22. Mtatiro SN, Makani, J, Mmbando B, et al. Genetic variants at HbF-modifier loci moderate anemia and leukocytosis in sickle cell disease in Tanzania. Am J Hematol 2015; 90:E1-E4.
23. Barbosa CG, Aleluia, ACM, Pacheco APAS, et al. Genetic modulation of HbF in Brazilians with HbSC disease and sickle cell anemia. Am J Hematol 2013; 88:923-924.
24. Sheehan VA, Luo Z, Flanagan JM, et al. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: Influence on laboratory and clinical phenotypes. Am J Hematol 2013; 88:571-576.
25. Akinsheye I, Alsultan A, Solovieff N, et al. Fetal hemoglobin in sickle cell anemia. Blood 2011; 118:19-27.
26. Platt OS, Orkin SH, Dover G, et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984; 74:652-656.
27. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995; 332:1317-1322.
28. Steinberg MH, McCarthy, WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol 2010; 85:403-408.
29. Wong TE, Brandow AM, Lim W, et al. Update on the use of hydroxyurea therapy in sickle cell disease. Blood 2014; 124:3850-3857.
30. Kinney TR, Helms, RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Blood 1999; 94:1550-1554.
31. Thornburg CD, Files, BA, Luo Z, et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood 2012; 120:4304-4310.
32. Wang WC, Ware, RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG). Lancet 2011; 377:1663-1672.
33. Wang WC, Helms, RW, Lynn HS, et al. Effect of hydroxyurea on growth in children with sickle cell anemia: Results of the HUG-KIDS Study. J Pediatr 2002; 140:225-229.
34. Aygun B, Mortier NA, Smeltzer MP, et al. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia. Am J Hematol 2013; 88:116-119.
35. Rana S, Houston, PE, Wang WC, et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics 2014; 134:465-472.
36. Stettler N, McKiernan CM, Melin CQ, et al. Proportion of adults with sickle cell anemia and pain crises receiving hydroxyurea. JAMA 2015; 313:1671-1672.
37. Hankins JS, Wynn, LW, Brugnara C, et al. Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anaemia. Br J Haematol 2008; 140:80-85.
38. Wang WF, Brugnara, C, Snyder C, et al. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: Results of the multi-centre CHAMPS trial. Br J Haematol 2011; 152:771-776.
39. Brun M, Bourdoulous S, Couraud PO, et al. Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells. Pharmacogenomics J 2003; 3:215-226.
40. Bartolucci P, Chaar V, Picot J, et al. Decreased sickle red blood cell adhesion to laminin by hydroxyurea is associated with inhibition of Lu/BCAM protein phosphorylation. Blood 2010; 116:2152-2159.
41. Robinson AJ, Kashanin DF, O'Dowd F, et al. Montelukast inhibition of resting and GM-CSF-stimulated eosinophil adhesion to VCAM-1 under flow conditions appears independent of cysLT(1)R antagonism. J Leukoc Biol 2008; 83:1522-1529.
42. Bartolucci P, Brugnara, C, Teixeira-Pinto A, et al. Erythrocyte density in sickle cell syndromes is associated with specific clinical manifestations and hemolysis. Blood 2012; 120:3136-3141.
43. Rakotoson MG, Di Liberto G, Audureau E, et al. Biological parameters predictive of percent dense red blood cell decrease under hydroxyurea. Orphanet J Rare Dis 2015; 10:57
44. Kutlar A, Reid ME, Inati A, et al. A dose-escalation phase IIa study of 2, 2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol 2013; 88:E255-E260.
45. Sankaran VG, Menne TF, Xu J, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 2008; 322:1839-1842.
46. Bauer DE, Kamran SC, Lessard S, et al. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science 2013; 342:253-257.
47. Marianna P, Kollia P, Akel S, et al. Valproic acid, trichostatin and their combination with hemin preferentially enhance gamma-globin gene expression in human erythroid liquid cultures. Haematologica 2001; 86:700-705.
48. Rosa RM, Bierer BE, Thomas R, et al. A study of induced hyponatremia in the prevention and treatment of sickle-cell crisis. N Engl J Med 1980; 303:1138-1143.
49. Lew VL, Bookchin RM. Ion transport pathology in the mechanism of sickle cell dehydration. Physiol Rev 2005; 85:179-200.
50. Brugnara C, Bunn HF, Tosteson DC. Regulation of erythrocyte cation and water content in sickle cell anemia. Science 1986; 232:388-390.
51. Franco RS, Palascak M, Thompson H, et al. KCl cotransport activity in light versus dense transferrin receptor-positive sickle reticulocytes. J Clin Invest 1995; 95:2573-2580.
52. Franco RS, Palascak, M, Thompson H, et al. Dehydration of transferrin receptor-positive sickle reticulocytes during continuous or cyclic deoxygenation: Role of KCl cotransport and extracellular calcium. Blood 1996; 88:4359-4365.
53. Crable SC, Hammond SM, Papes R, et al. Multiple isoforms of the KC1 cotransporter are expressed in sickle and normal erythroid cells. Exp Hematol 2005; 33:624-631.
54. Brugnara C, Van Ha T, Tosteson DC. Acid pH induces formation of dense cells in sickle erythrocytes. Blood 1989; 74:487-495.
55. Brugnara C, De Franceschi L, Alper SL. Inhibition of Ca(2+)-dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. J Clin Invest 1993; 92:520-526.
56. Etzion Z, Tiffert T, Bookchin RM, et al. Effects of deoxygenation on active and passive Ca2+ transport and on the cytoplasmic Ca2+ levels of sickle cell anemia red cells. J Clin Invest 1993; 92:2489-2498.
57. Lew VL, Ortiz OE, Bookchin RM. Stochastic nature and red cell population distribution of the sickling-induced Ca2+ permeability. J Clin Invest 1997; 99:2727-2735.
58. Lew VL, Tiffert, T, Etzion Z, et al. Distribution of dehydration rates generated by maximal Gardos-channel activation in normal and sickle red blood cells. Blood 2005; 105:361-367.
59. Rivera A, Jarolim P, Brugnara C. Modulation of gardos channel activity by cytokines in sickle erythrocytes. Blood 2002; 99:357-363.
60. Vandorpe DH, Xu C, Shmukler BE, et al. Hypoxia activates a Ca(2+)-permeable cation conductance sensitive to carbon monoxide and to GsMTx-4 in human and mouse sickle erythrocytes. PLoS One 2010; 5. e8732.
61. Joiner CH, Dew A, Ge DL. Deoxygenation-induced cation fluxes in sickle cells: Relationship between net potassium efflux and net sodium influx. Blood Cells 1988; 13:339-358.
62. Joiner CH, Claussen W, Yasin Z, et al. Dipyridamole inhibits in vitro deoxygenation-induced cation fluxes in sickle red blood cells at the membrane concentration achievable in blood. Blood 1997; 90:125.
63. De Franceschi L, Bachir D, Galacteros F, et al. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 1997; 100:1847-1852.
64. De Franceschi L, Bachir, D, Galacteros F, et al. Oral magnesium pidolate: Effects of long-term administration in patients with sickle cell disease. Br J Haematol 2000; 108:248-289.
65. Benjamin LJ, Berkowitz, LR, Orringer E, et al. A collaborative, double-blind randomized study of cetiedil citrate in sickle cell crisis. Blood 1986; 67:1442-1447.
66. Ataga KI, DeCastro LM, Swerdlow P, et al. Efficacy and safety of the Gardos channel inhibitor, ICA-17043, in patients with sickle cell anemia. Blood 2004; 104:33.
67. Brugnara C, Gee B, Armsby CC, et al. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 1996; 97:1227-1234.
68. Ataga KI, Reid M, Ballas SK, et al. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: A phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043). Br J Haematol 2011; 153:92-104.
69. Rivera A. Reduced sickle erythrocyte dehydration in vivo by endothelin-1 receptor antagonists. Am J Physiol Cell Physiol 2007; 293:C960-966.
70. Castro O, Pollen WN, Finke H, et al. Improvement of sickle cell anemia by iron-limited erythropoiesis. Am J Hematol 1994; 47:74-81.
71. Boucher N, Manigne P, Kanfer A, et al. Prevention of sickle cell crises with multiple phlebotomies. Arch Pediatr 2000; 7:249-255.
72. De Furia Fg Fau-Miller DR, Miller Dr Fau - Cerami A, Cerami, A, Fau-Manning JM, et al. The effects of cyanate in vitro on red blood cell metabolism and function in sickle cell anemia. J Clin Invest 1972; 51:566-574.
73. Deiderich DA, Trueworthy RC, Gill P, et al. Hematologic and clinical responses in patients with sickle cell anemia after chronic extracorporeal red cell carbamylation. J Clin Invest 1976; 58:642-653.
74. Keidan AJ, White RD, Huehns ER, et al. Effect of BW12C on oxygen affinity of haemoglobin in sickle-cell disease. Lancet 327:831-834.
75. Orringer E, Huffman J, Guaspari L, et al. A clinical-study of the safety, pharmacokinetics, and pharmacodynamics of intravenous infusions of 12C79 in sickle-cell disease patients not in crisis. Clin Res 1991; 39:238-238.
76. Abraham D, Mehanna A, Wireko F, et al. Vanillin, a potential agent for the treatment of sickle cell anemia. Blood 1991; 77:1334-1341.
77. Garcia AF, Cabal C, Losada J, et al. In vivo action of Vanillin on delay time determined by magnetic relaxation. Hemoglobin 2005; 29:181-187.
78. Hannemann A, Cytlak UMC, Gbotosho OT, et al. Effects of o-vanillin on K+ transport of red blood cells from patients with sickle cell disease. Blood Cells Mol Dis 2014; 53:21-26.
79. Abdulmalik O, Ghatge MS, Musayev FN, et al. Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin. Acta Crystallogr Sect D Biol Crystallogr 2011; 67:920-928.
80. Verduzco LA, Nathan DG. Sickle cell disease and stroke. Blood 2009; 114:5117-5125.
81. Arya R, Rolan PE, Wootton R, et al. Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia. Br J Haematol 1996; 93:817-821.
82. Abdulmalik O, Safo MK, Chen QK, et al. 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Br J Haematol 2005; 128:552-561.
83. Hannemann A, Cytlak UM, Rees DC, et al. Effects of 5-hydroxymethyl-2-furfural on the volume and membrane permeability of red blood cells from patients with sickle cell disease. J Physiol Lond 2014; 592:4039-4049.
84. Lawrence MP, Mendelsohn LG, Saiyed R, et al. Phase 1 clinical trial of the candidate anti-sickling agent Aes-103 in adults with sickle cell anemia. Blood 2013; 122:1009-1009.
85. Belcher JD, Young M, Chen CS, et al. MP4CO, a pegylated hemoglobin saturated with carbon monoxide, is a modulator of HO-1, inflammation, and vaso-occlusion in transgenic sickle mice. Blood 2013; 122:2757-2764.
86. Kaul DK, Chen D, Zhan J. Adhesion of sickle cells to vascular endothelium is critically dependent on changes in density and shape of the cells. Blood 1994; 83:3006-3017.
87. Kaul DK. Sickle red cell adhesion: Many issues and some answers. Transfus Clin Biol 2008; 15:51-55.
88. Nelson RM, Cecconi O, Roberts WG, et al. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993; 82:3253-3258.
89. Finger EB, Puri KD, Alon R, et al. Adhesion through L-selectin requires a threshold hydrodynamic shear. Nature 1996; 379:266-269.
90. Lawrence MB, Kansas GS, Kunkel EJ, et al. Threshold levels of fluid shear promote leukocyte adhesion through selectins (CD62L, P, E). J Cell Biol 1997; 136:717-727.
91. Matsui NM, Varki A, Embury SH. Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. Blood 2002; 100:3790-3796.
92. Koenig A, Norgard-Sumnicht K, Linhardt R, et al. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998; 101:877-889.
93. Kutlar A, Ataga KI, McMahon L, et al. A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease. Am J Hematol 2012; 87:536-539.
94. Qari MH, Aljaouni SK, Alardawi MS, et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thromb Haemost 2007; 98:392-396.
95. Batchvarova M, Shan SQ, Zennadi R, et al. Sevuparin reduces adhesion of both sickle red cells and leukocytes to endothelial cells in vitro and inhibits vaso-occlusion in vivo. Blood 2013; 122:2.
96. Wun T, Styles L, DeCastro L, et al. Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia. PLos One 2014; 9:12.
97. De Castro LM, Wun T, Lanzkron S, et al. Effects of GMI 1070, a pan-selectin inhibitor, on pain intensity and opioid utilization in sickle cell disease. Blood 2013; 122:775.
98. McCavit TL, Krishnamurti L, Hsu LL, et al. An analysis of the pediatric sub-group from the phase 2 study of GMI 1070-A novel agent for the vaso-occlusive crisis of sickle cell anemia. Blood 2013; 122:2206.
99. Telen MJ, Wun T, McCavit TL, et al. GMI 1070: Reduction in time to resolution of vaso-occlusive crisis and decreased opioid use in a prospective, randomized, multi-center double blind, adaptive phase 2 study in sickle cell disease. Blood 2013; 122:(abstract).
100. Telen MJ, Wun T, McCavit TL, et al. Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood 2015; 125:2656-2664.
101. Gutsaeva DR, Parkerson JB, Yerigenahally SD, et al. Inhibition of cell adhesion by anti-P-selectin aptamer: A new potential therapeutic agent for sickle cell disease. Blood 2011; 117:727-735.
102. Orringer EP, Casella JF, Ataga KI, et al. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease - A randomized controlled trial. JAMA 2001; 286:2099-2106.
103. Cheung ATW, Chan MS, Ramanujam S, et al. Effects of poloxamer 188 treatment on sickle cell vaso-occlusive crisis: Computer-assisted intravital microscopy study. J Invest Med 2004; 52:402-406.
104. De Castro LM, Zennadi R, Jonassaint JC, et al. Effect of propranolol as antiadhesive therapy in sickle cell disease. Clin Transl Sci 2012; 5:437-444.
105. Schwam E, Nicholas T, Chew R, et al. A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor. Curr Alzheimer Res 2014; 11:413-421.
106. Manwani D, Chen G, Carullo V, et al. Single-dose intravenous gamamglobulin can stabilize neutrophil Mac-1 activation in sickle cell pain crises. Am J Hematol 2015; 90:381-385.
107. Wun T, Soulieres D, Frelinger AL, et al. A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol Oncol 2013; 6:17.
108. Castro O, Brambilla DJ, Thorington B, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 1994; 84:643-649.
109. Kinney TR, Sleeper LA, Wang WC, et al. Silent cerebral infarcts in sickle cell anemia: A risk factor analysis. The Cooperative Study of Sickle Cell Disease. Pediatrics 1999; 103:640-645.
110. Li J, Kim K, Hahm E, et al. Neutrophil AKT2 regulates heterotypic cell-cell interactions during vascular inflammation. J Clin Invest 2014; 124:1483-1496.
111. Zhang Y Berka V, Song A, et al. Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression. J Clin Invest 2014; 124:2750-2761.
112. Vercellotti GM, Belcher JD. Not simply misshapen red cells: Multimolecular and cellular events in sickle vaso-occlusion. J Clin Invest 2014; 124:1462-1465.
113. Haynes J, Baliga BS, Obiako B, et al. Zileuton induces hemoglobin F synthesis in erythroid progenitors: Role of the l-arginine-nitric oxide signaling pathway. Blood 2004; 103:3945-3950.
114. Macari ER, Lowrey CH. Induction of human fetal hemoglobin via the NRF2 antioxidant response signaling pathway. Blood 2011; 117:5987-5997.
115. Promsote W, Makala L, Li B, et al. Monomethylfumarate induces γ-globin expression and fetal hemoglobin production in cultured human retinal pigment epithelial (RPE) and erythroid cells, and in intact retina. Invest Ophthalmol Vis Sci 2014; 55:5382-5393.
116. Bereal-Williams C, Machado RF, McGowan V, et al. Atorvastatin reduces serum cholesterol and triglycerides with limited improvement in vascular function in adults with sickle cell anemia. Haematologica 2012; 97:1768-1770.
117. Hoppe C, Kuypers F, Larkin S, et al. A pilot study of the short-term use of simvastatin in sickle cell disease: Effects on markers of vascular dysfunction. Br J Haematol 2011; 153:655-663.
118. Kalish BT, Matte A, Andolfo I, et al. Dietary ω-3 fatty acids protect against vasculopathy in a transgenic mouse model of sickle cell disease. Haematologica 2015; 100:870-880.
119. Zennadi R. MEK inhibitors, novel anti-adhesive molecules, reduce sickle red blood cell adhesion in vitro and in vivo, and vasoocclusion in vivo. PLos One 2014; 9:11.
120. Pawloski JR, Hess DT, Stamler JS. Impaired vasodilation by red blood cells in sickle cell disease. Proc Natl Acad Sci USA 2005; 102:2531-2536.
121. Reiter CD, Wang XD, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002; 8:1383-1389.
122. Gladwin MT, Sachdev, V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350:886-895.
123. Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med 2008; 359:2254-2265.
124. Parent F, Bachir D, Inamo J, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 2011; 365:44-53.
125. Bunn HF, Nathan DG, Dover GJ, et al. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood 2010; 116:687-692.
126. Gladwin MT, Barst RJ, Castro OL, et al. Pulmonary hypertension and NO in sickle cell. Blood 2010; 116:852-854.
127. Nathan DG Guilt by association. Blood 2011; 118:3758-3759.
128. Weiner DL, Hibberd PL, Betit P, et al. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. JAMA 2003; 289:1136-1142.
129. Gladwin MT, Kato GJ, Weiner D, et al. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis a randomized controlled trial. JAMA 2011; 305:893-902.
130. Atz AM, Wessel DL. Inhaled nitric oxide in sickle cell disease with acute chest syndrome. Anesthesiology 1997; 87:988-990.
131. Sullivan KJ, Goodwin SR, Evangelist J, et al. Nitric oxide successfully used to treat acute chest syndrome of sickle cell disease in a young adolescent. Crit Care Med 1999; 27:2563-2568.
132. Belhassen L, Pelle G, Sediame S, et al. Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood 2001; 97:1584-1589.
133. de Montalembert M, Aggoun Y, Niakate A, et al. Endothelial-dependent vasodilation is impaired in children with sickle cell disease. Haematologica 2007; 92:1709-1710.
134. Machado RF, Barst RJ, Yovetich NA, et al. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood 2011; 118:855-864.
135. Burnett AL, Anele UA, Trueheart IN, et al. Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease. Am J Med 2014; 127:664-668.
136. Barst RJ, Mubarak KK, Machado RF, et al. Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: Results of the ASSET studies. Br J Haematol 2010; 149:426-435.
137. Morris CR. Alterations of the arginine metabolome in sickle cell disease: A growing rationale for arginine therapy. Hematol/Oncol Clin North Am 2014; 28:301-321.
138. Morris CR, Kuypers FA, Lavrisha L, et al. A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica 2013; 98:1375-1382.
139. Schaer DJ, Buehler PW, Alayash AI, et al. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood 2013; 121:1276-1284.
140. Chintagari NR, Nguyen J, Belcher JD, et al. Haptoglobin attenuates hemoglobin-induced heme oxygenase-1 in renal proximal tubule cells and kidneys of a mouse model of sickle cell disease. Blood Cells Mol Dis 2015; 54:302-306.
141. Boretti FS, Baek JH, Palmer AF, et al. Modeling hemoglobin and hemoglobin:haptoglobin complex clearance in a non-rodent species-pharmacokinetic and therapeutic implications. Front Physiol 2014; 5:385
142. Gonzalez P, Hackney AC, Jones S, et al. A phase I/II study of polymerized bovine hemoglobin in adult patients with sickle cell disease not in crisis at the time of study. J Invest Med 1997; 45:258-264.
143. Natanson C, Kern SJ, Lurie P, et al. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: A meta-analysis. JAMA 2008; 299:2304-2312.
144. http://www.sec.gov/Archives/edgar/data/1420031/000104746915003012/a2223903z10-k.htm. Last accessed on July 28, 2015.
145. Romero Z, Urbinati F, Geiger S, et al. β-globin gene transfer to human bone marrow for sickle cell disease. J Clin Invest 2013; 123:3317-3330.
146. Urbinati F, Hargrove PW, Geiger S, et al. Potentially therapeutic levels of anti-sickling globin gene expression following lentivirus-mediated gene transfer in sickle cell disease bone marrow CD34+ cells. Exp Hematol 2015; 43:346-351.
147. Hoban MD, Cost GJ, Mendel MC, et al. Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. Blood 2015; 125:2597-2604.
148. Ledford H. CRISPR, the disruptor. Nature 2015; 522:20-24.
149. Dedeken L, Le PQ, Azzi N, et al. Haematopoietic stem cell transplantation for severe sickle cell disease in childhood: A single centre experience of 50 patients. Br J Haematol 2014; 165:402-408.
150. Bernaudin F, Socie G, Kuentz M, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 2007; 110:2749-2756.
151. Locatelli F, Kabbara N, Ruggeri A, et al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood 2013; 122:1072-1078.
152. Lê PQ, Gulbis, Dedeken L, Dupont S, et al. Survival among children and adults with sickle cell disease in Belgium: Benefit from hydroxyurea treatment. Pediatr Blood Cancer, in press.
153. Hsieh MM, Fitzhugh CD, Weitzel RP, et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA 2014; 312:48-56.
154. Horan JT, Haight A, Dioguardi JL, et al. Using fludarabine to reduce exposure to alkylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: Results of a dose de-escalation trial. Biol Blood Marrow Transplant 2015; 21:900-905.
155. Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: A critical reappraisal. Blood 2012; 120:3647-3656.
156. Poggiali E, Cassinerio E, Zanaboni L, et al. An update on iron chelation therapy. Blood Transf 2012; 10:411-422.
157. Vichinsky E, Torres M, Minniti CP, et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: Two-year results including pharmacokinetics and concomitant hydroxyurea. Am J Hematol 2013; 88:1068-1073.
158. Mahadeo KM, Oyeku S, Taragin B, et al. Increased prevalence of osteonecrosis of the femoral head in children and adolescents with sickle-cell disease. Am J Hematol 2011; 86:806-808.
159. Poignard A, Flouzat-Lachaniette CH, Amzallag J, et al. The natural progression of symptomatic humeral head osteonecrosis in adults with sickle cell disease. J Bone Joint Surg Am 2012;94:156-162.
160. Issa K, Naziri Q, Maheshwari AV, et al. Excellent results and minimal complications of total hip arthroplasty in sickle cell hemoglobinopathy at mid-term follow-up using cementless prosthetic components. J Arthroplast 2013; 28:1693-1698.
161. Nath KA, Hebbel RP. Sickle cell disease: Renal manifestations and mechanisms. Nat Rev Nephrol 2015; 11:161-171.
162. Gosmanova EO, Zaidi S, Wan JY, et al. Prevalence and progression of chronic kidney disease in adult patients with sickle cell disease. J Invest Med 2014; 62:804-807.
163. Bodas P, Huang A, O'Riordan MA, et al. The prevalence of hypertension and abnormal kidney function in children with sickle cell disease -a cross sectional review. BMC Nephrol 2013; 14:6.
164. Laurin LP, Nachman PH, Desai PC, et al. Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease. Nephrol Dial Transplant 2014; 29:1211-1218.
165. Lionnet F, Hammoudi N, Stojanovic KS, et al. Hemoglobin sickle cell disease complications: A clinical study of 179 cases. Haematol-Hematol J 2012; 97:1136-1141.
166. Wanek J, Gaynes B, Lim JI, et al. Human bulbar conjunctival hemodynamics in hemoglobin SS and SC disease. Am J Hematol 2013; 88:661-664.
167. Nero AC, Akuete K, Reeves SL, et al. Pneumococcal vaccination rates in children with sickle cell disease. J Public Health Manag Pract 2014; 20:587-590.
168. Payne AB, Link-Gelles R, Azonobi I, et al. Invasive pneumococcal disease among children with and without sickle cell disease in the United States, 1998 to 2009. Pediatr Infect Dis J 2013; 32:1308-1312.
169. Beverung LM, Brousseau D, Hoffmann RG, et al. Ambulatory quality indicators to prevent infection in sickle cell disease. Am J Hematol 2014; 89:256-260.
170. Soderblom EJ, Thompson JW, Schwartz EA, et al. Proteomic analysis of ERK1/2-mediated human sickle red blood cell membrane protein phophorylation. Clin Proteom 2013; 10:1.